Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review

Yudai Hinata; Nobumasa Ohara; Yuhki Sakurai; Ryo Koda; Yuichiro Yoneoka; Toshinori Takada; Noboru Hara; Tsutomu Nishiyama

doi:10.12659/AJCR.931639

15 July 2021 : Case report Japan

Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review

Unusual clinical course

Yudai Hinata^1BCD, Nobumasa Ohara^1ABCDEF*, Yuhki Sakurai^1CD, Ryo Koda^2BCD, Yuichiro Yoneoka^3CD, Toshinori Takada^4CD, Noboru Hara^5BD, Tsutomu Nishiyama^5BD

DOI: 10.12659/AJCR.931639

Am J Case Rep 2021; 22:e931639

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Table 2. Endocrinological investigation.A: Rapid adrenocorticotropic hormone stimulation test.

		Time (min)
		Basal	30	60
August 2019	Cortisol (μg/dL)	7.4	14.6	17.1
November 2019	Cortisol (μg/dL)	1.4	6.2	8.5
Tetracosactide acetate (0.25 mg) was administered i.v. in the morning.

Back to the Article

Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review

Your Privacy